Biomarkers

Protein Biomarkers can be used as biomarkers for early recognition of cancer particularly used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will experience an underlying CT scan to decide if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-respectable stage III and IV disease and a biopsy will be attempted to confirm pancreatic tumour by H&E pathological assay. The presence of cancerous cells by means of pathology is very challenging because of high quantities of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will just initiate on definitive diagnosis of pancreatic cancer. These will see particularly stains neoplastic pancreatic cells would empower the pathologist to confidently diagnose pancreatic cancer and in this way offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been recognized as a highly sensitive (98%) and particular (95%) IHC marker for pancreatic cancer and CRT is looking for a partner to build up an IHC based test to distinguish BI-010 in fine needle suction biopsies from biopsy tests.

 

    Related Conference of Biomarkers

    March 18-19, 2024

    5th Global Summit on Oncology and Hematology

    Zurich, Switzerland
    June 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Barcelona, Spain
    July 11-12, 2024

    24th World Congress on Cancer and Diagnostics

    Vancouver, Canada
    July 18-19, 2024

    14th World Congress on Breast Cancer

    Paris, France
    September 19-20, 2024

    25th World Congress on Cancer Summit

    Paris, France

    Biomarkers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in